Marcos Rubio-Fernández

Marcos Rubio-Fernández

Auto-generated profile, based on publicly available information

Marcos Rubio-Fernández

Bioinformatics Unit, Spanish National Cancer Research Centre (CNIO) , Calle Melchor Fernández Almagro, 3 , Madrid 28029

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 October 2024 in NAR Cancer
Verified
Journal Article
Open access
MJMaría José Jiménez-Santos
María José Jiménez-Santos
SGSantiago García-Martín
Santiago García-Martín
MRMarcos Rubio-Fernández
Marcos Rubio-Fernández
Gonzalo Gomez-LopezGonzalo Gomez-Lopez
Gonzalo Gomez-Lopez
FAFátima Al-Shahrour
Fátima Al-Shahrour
Breast cancer patients are categorized into three subtypes with distinct treatment approaches. Precision oncology has increased patient outcomes by targeting the specific molecular alterations of tumours, yet challenges remain. Treatment failure persists due to the coexistence of several malignant subpopulations with different drug sensitivities within the same tumour, a phenomenon known as intratumour heterogeneity (ITH). This heterogeneity has been extensively studied from a tumour-centric view, but recent insights underscore the role of the tumour microenvironment in treatment response. Our research utilizes spatial transcriptomics data from breast cancer patients to predict drug sensitivity. We observe diverse response patterns across tumour, interphase and microenvironment regions, unveiling a sensitivity and functional gradient from the tumour core to the periphery. Moreover, we find tumour therapeutic clusters with different drug responses associated with distinct biological functions driven by unique ligand-receptor interactions. Importantly, we identify genetically identical subclones with different responses depending on their location within the tumour ducts. This research underscores the significance of considering the distance from the tumour core and microenvironment composition when identifying suitable treatments to target ITH. Our findings provide critical insights into optimizing therapeutic strategies, highlighting the necessity of a comprehensive understanding of tumour biology for effective cancer treatment.

11 March 2020 in Current Protocols in Mouse Biology
Verified
Journal Article
Open access
PDF file
AFAlmudena Fernández
Almudena Fernández
MMMatias Morin
Matias Morin
DMDiego Muñoz‐Santos
Diego Muñoz‐Santos
SJSantiago Josa
Santiago Josa
AMAndrea Montero
Andrea Montero
LMLluís Montoliu
Lluís Montoliu
The simple protocol described in this article aims to provide all required information, as a comprehensive, easy‐to‐follow step‐by‐step method, to ensure the generation of the expected genome‐edited mice. Here, we provide protocols for the preparation of CRISPR‐Cas9 reagents for microinjection and electroporation into one‐cell mouse embryos to create knockout or knock‐in mouse models, and for genotyping the resulting offspring with the latest innovative next‐generation sequencing methods. © 2020 by John Wiley & Sons, Inc.Basic Protocol 1: Designing the best RNA guide for your gene disruption/editing strategyBasic Protocol 2: Preparing and validating CRISPR‐Cas9 reagentsBasic Protocol 3: Preparing and injecting CRISPR‐Cas9 compounds into fertilized mouse oocytesBasic Protocol 4: Genotyping genome‐edited miceSupport Protocol: Genotyping for CRISPR‐generated “indel” mutations

4 June 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
MRMarcos Rubio-Fernández
Marcos Rubio-Fernández
Mary Luz UribeMary Luz Uribe
Mary Luz Uribe
JVJavier Vicente-Tejedor
Javier Vicente-Tejedor
FGFrancisco Germain
Francisco Germain
CSCristina Susín-Lara
Cristina Susín-Lara
JCJesús Cruces
Jesús Cruces
Hypoglycosylation of α-dystroglycan (α-DG) resulting from deficiency of protein O-mannosyltransferase 1 (POMT1) may cause severe neuromuscular dystrophies with brain and eye anomalies, named dystroglycanopathies. The retinal involvement of these disorders motivated us to generate a conditional knockout (cKO) mouse experiencing a Pomt1 intragenic deletion (exons 3–4) during the development of photoreceptors, mediated by the Cre recombinase expressed from the cone-rod homeobox (Crx) gene promoter. In this mouse, retinal α-DG was unglycosylated and incapable of binding laminin. Retinal POMT1 deficiency caused significant impairments in both electroretinographic recordings and optokinetic reflex in Pomt1 cKO mice, and immunohistochemical analyses revealed the absence of β-DG and of the α-DG-interacting protein, pikachurin, in the outer plexiform layer (OPL). At the ultrastructural level, noticeable alterations were observed in the ribbon synapses established between photoreceptors and bipolar cells. Therefore, O-mannosylation of α-DG in the retina carried out by POMT1 is crucial for the establishment of proper synapses at the OPL and transmission of visual information from cones and rods to their postsynaptic neurons.

14 January 2020 in Journal of Neuroinflammation
Verified
Journal Article
Open access
PDF file
FBFernando Bartolome
Fernando Bartolome
DADesiree Antequera
Desiree Antequera
MCMacarena de la Cueva
Macarena de la Cueva
MRMarcos Rubio-Fernandez
Marcos Rubio-Fernandez
NCNerea Castro
Nerea Castro
Eva M. CarroEva M. Carro
Eva M. Carro
Background: The increasing risk of obesity and diabetes among other metabolic disorders are the consequence of shifts in dietary patterns with high caloric-content food intake. We previously reported that megalin regulates energy homeostasis using blood-brain barrier (BBB) endothelial megalin-deficient (EMD) mice, since these animals developed obesity and metabolic syndrome upon normal chow diet administration. Obesity in mid-life appears to be related to greater dementia risk and represents an increasing global health issue. We demonstrated that EMD phenotype induced impaired learning ability and recognition memory, neurodegeneration, neuroinflammation, reduced neurogenesis, and mitochondrial deregulation associated with higher mitochondrial mass in cortical tissues. Methods: EMD mice were subjected to normal chow and high-fat diet (HFD) for 14 weeks and metabolic changes were evaluated. Results: Surprisingly, BBB megalin deficiency protected against HFD-induced obesity improving glucose tolerance and preventing hepatic steatosis. Compared to wild type (wt), the brain cortex in EMD mice showed increased levels of the mitochondrial biogenesis regulator, peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α), and uncoupling protein 2 (UCP2), a thermogenic protein involved in the regulation of energy metabolism. This agreed with the previously found increased mitochondrial mass in the transgenic mice. Upon HFD challenge, we demonstrated these two proteins were found elevated in wt mice but reported no changes over the already increased levels in EMD animals. Conclusion: We propose a protective role for megalin on diet-induce obesity, suggesting this could be related to metabolic disturbances found in dementia through brain endocrine system communications.

25 November 2013 in Journal of Child Neurology
Verified
Journal Article
Closed access
MRMadalina Raducu
Madalina Raducu
RCRocío P. Cotarelo
Rocío P. Cotarelo
RSRogelio Simón
Rogelio Simón
ACAna Camacho
Ana Camacho
MRMarcos Rubio-Fernández
Marcos Rubio-Fernández
JCJesús Cruces
Jesús Cruces
Muscle-eye-brain disease is a congenital muscular dystrophy characterized by structural brain and eye defects. Here, we describe a 12-year-old boy with partial agenesis of corpus callosum, ventriculomegaly, flattened brain stem, diffuse pachygyria, blindness, profound cognitive deficiencies, and generalized muscle weakness, yet without a clear dystrophic pattern on muscle biopsy. There was no glycosylation of α-dystroglycan and the genetic screening revealed a novel truncating mutation, c.1545delC (p.Tyr516Thrfs*21), and a previously identified missense mutation, c.1469G>A (p.Cys490Tyr), in the protein O -mannose beta-1,2- N -acetylglucosaminyltransferase 1 ( POMGNT1 ) gene. These findings broaden the clinical spectrum of muscle-eye-brain disease to include pronounced hypotonia with severe brain and eye malformations, yet with mild histopathologic changes in the muscle specimen, despite the absence of glycosylated α-dystroglycan.

21 February 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
MJMaría José Jiménez-Santos
María José Jiménez-Santos
SGSantiago García-Martín
Santiago García-Martín
MRMarcos Rubio-Fernández
Marcos Rubio-Fernández
Gonzalo Gomez-LopezGonzalo Gomez-Lopez
Gonzalo Gomez-Lopez
FAFátima Al-Shahrour
Fátima Al-Shahrour
Breast cancer is a heterogeneous disease that has the highest incidence and mortality rate among cancers in women worldwide. Breast cancer patients are stratified into three clinical subtypes with different treatment strategies and prognostic values. The development of targeted therapies against the biomarkers that define these strata constitutes one of the precedents of precision oncology, which aims to provide tailored treatments to cancer patients by targeting the molecular alterations found in each tumour. Although this approach has increased patient outcomes, many treatment failure cases still exist. Drug ineffectiveness and relapse have been associated with the coexistence of several malignant subpopulations with different drug sensitivities within the same lesion, a phenomenon known as intratumor heterogeneity. This heterogeneity has been extensively studied from a tumour-centric view, but recently, it has become evident that the tumour microenvironment plays a crucial role in intratumor heterogeneity. However, few studies consider the tumour-microenvironment interplay and its influence on drug sensitivity. In this work, we predict the sensitivity of 10x Visium spatial transcriptomics data from 9 breast cancer patients to >1,200 drugs and verify different response patterns across the tumour, interphase and microenvironment regions. We uncover a sensitivity continuum from the tumour core to the periphery accompanied by a functional gradient. Moreover, we identify conserved therapeutic clusters with distinct response patterns within the tumour region. We link the specific drug sensitivities of each therapeutic cluster to different ligand-receptor interactions that underpin distinct biological functions. Finally, we demonstrate that genetically identical cancer spots may belong to different therapeutic clusters and that this therapeutic heterogeneity is related to their location at the edge or core of tumour ducts. These results highlight the importance of considering the distance to the tumour core and the microenvironment composition when identifying suitable treatments to target intratumor heterogeneity.